Stent Mania US Style
For the last couple of years, J&J has all but owned the US market for coronary stents, in the process creating an $800 million business with 90-95% market share. But now it's bracing for a host of competitors, including Guidant's much anticipated product.
You may also be interested in...
Today, carotid artery stenting is an accepted less-invasive alternative to surgical endarterectomy for carefully selected patients, particularly those at significant surgical risk, and market projections are very positive. But, the field still has a long way to go before this procedure is considered routine.
A short summary of recent market and product developments in Interventional Cardiology, Spine Surgery, and Aesthetics, including: DES Safety Panel Weighs the Evidence; Percutaneous Lubar Fusion, and New Dermal Fillers.
'Drug-coated stents' success will usher in a new era in interventional cardiology, argues Marty Leon, MD, one of the nation's top interventional cardiologists. He sees interventionalists taking the lead in new areas and expanding their presence in others, such as interventional radiology, and interventional neurology. New nanotechnologies will be used to manufacture stents to ensure better adhesion of therapeutic agents, and these will need new access technologies and imaging systems, for example.